Correlation of thiamine metabolite levels with cognitive function in the non-demented elderly

Jingwen Lu^{1,*}, Xiaoli Pan^{1,*}, Guoqiang Fei^{1,*}, Changpeng Wang¹, Lei Zhao¹, Shaoming Sang², Huimin Liu², Meng Liu², Hui Wang³, Zhiliang Wang³, Chunjiu Zhong^{1,2}

¹Department of Neurology, Zhongshan Hospital and Shanghai Medical College, Fudan University, Shanghai 200032, China

²State Key Laboratory of Medical Neurobiology and Institutes of Brain Science, Fudan University, Shanghai 200032, China

³Regional Health Service Center of Xujiahui, Xuhui District, Shanghai 200030, China

*These authors contributed equally to this work.

Corresponding author: Chunjiu Zhong. E-mail: zhongcj@163.com

ABSTRACT

Thiamine metabolism is critical for glucose metabolism and also vital for brain function, which is susceptible to decline in the elderly. This study aimed to investigate whether thiamine metabolites correlate with cognitive function in the non-demented elderly and their impact factors. Volunteers >60 years old were recruited and their blood thiamine metabolites and Mini-Mental State Examination (MMSE) scores were measured. The apolipoprotein E (APOE) genotype, routine blood parameters, liver and kidney function, and levels of fasting blood glucose and triglycerides were also measured. The results showed that the thiamine diphosphate (TDP) level weakly correlated with MMSE score in the non-demented elderly. Participants with high TDP levels performed better in *Recall* and *Attention and Calculation* than those with low TDP. TDP levels were associated with the APOE ϵ 2 allele, body mass index, hemoglobin level, fasting blood glucose, and triglycerides. Our results suggest that TDP, which is easily affected by many factors, impacts cognitive function in the elderly.

Keywords: thiamine diphosphate; cognitive function; non-demented elderly

INTRODUCTION

The human brain accounts for only 2% of body weight

but consumes nearly 25% of the total body glucose in the resting awake state^[1]. Since glucose is the predominant energy substrate for oxidative processes in the brain^[2], appropriate glucose metabolism is vital for sustaining brain functions. The elderly are susceptible to a decline in brain functions^[3, 4]. Further, the severity of cognitive impairment, the most common manifestation of declining brain function, is significantly correlated with a reduction in brain glucose metabolism^[5–8]. Clarifying the cause and mechanism of reduced brain glucose metabolism in the elderly will help in the search for preventive and therapeutic target(s) against cognitive impairment.

Thiamine metabolism is vital for glucose metabolism. Thiamine diphosphate (TDP), the active form of thiamine, is a critical coenzyme of three key enzymes in glucose metabolism: pyruvate dehydrogenase complex and α -ketoglutarate dehydrogenase complex in the Krebs cycle, and transketolase in the pentose phosphate pathway. It has been demonstrated that the elderly tend to suffer from thiamine deficiency with aging itself, rather than co-existent illnesses^[9]. Patients with Alzheimer's disease (AD), the most common type of dementia, have reduced TDP content, reduced activity of thiamine-dependent enzymes^[10–12], and brain glucose hypometabolism. Therefore, abnormal thiamine metabolism may be a pathogenic factor for the declined brain glucose metabolism in the elderly.

However, studies on the correlation between thiamine metabolism and cognitive function in the non-demented elderly are insufficient and the results are controversial^[13–15]. The inconsistent results may be partially attributed to the

small sample sizes in some studies. Also, the methodology for determining the content of thiamine and its derivatives needs to be considered. The previous studies mainly evaluated the thiamine metabolites indirectly, using methods such as the erythrocyte transketolase activity assay that records the difference in transketolase activity before and after addition of TDP as a consequence of diminished coenzyme concentration^[13, 15]. The precise levels of thiamine and its derivatives and the extent of thiamine deficiency are unknown. Recently, high-performance liquid chromatographic (HPLC) fluoroscopy has been used to determine the levels of free thiamine, thiamine monophosphate (TMP), and TDP in whole blood, and has proved to be rapid, accurate, and convenient^[16, 17].

So far, little is known about the status of thiamine metabolites in the non-demented elderly in China, which has the largest and most rapidly ageing population in the world. The aim of this study was to investigate the correlation of thiamine metabolites with cognitive function

in the non-demented elderly living on Xujiahui Street in the Xuhui District of Shanghai, China. In addition, as multiple factors such as apolipoprotein E (*APOE*) genotype, age, and educational background are involved in cognitive function, we also analyzed the relationship between TDP levels and these factors.

PARTICIPANTS AND METHODS

Participants

Volunteers were recruited from the Physical Examination Department at the Regional Health Service Center of Xujiahui from April 1 to December 31, 2012. Participants were >60 years old and lived on Xujiahui Street, Xuhui District, Shanghai, China. All participants gave informed consent. Information on history of diseases, current medications, and supplementation with vitamins and other health-care products was collected by questionnaire. Participants with major disorders of the gastrointestinal

Fig. 1. Flowchart of this study.

Table 1. Demographic and clinical characteristics of participants with normal cognitive function ($n=611$, mean $\pm$ SD)

Variables	Value (range)
Age (years)	72.30 $\pm$ 5.89 (63–91)
Males (%)	263 (43.04)
MMSE scores	27.83 $\pm$ 2.38 (18–30)
Education (years)	9.27 $\pm$ 4.96 (0–16)
TDP (nmol/L)	118.60 $\pm$ 23.25 (61.75–189.2)
TMP (nmol/L)	3.70 $\pm$ 2.16 (0–12.16)
Thiamine (nmol/L)	3.47 $\pm$ 2.80 (0–29.65)
Hemoglobin (g/L)	134.1 $\pm$ 13.72 (83.0–169.0)
Fasting plasma glucose (mmol/L)	6.04 $\pm$ 1.56 (4.01–15.82)
Triglyceride (mmol/L)	1.53 $\pm$ 0.98 (0.33–11.32)
Alanine aminotransferase (U/L)	22.19 $\pm$ 10.78 (6.7–91.6)
Creatinine (mmol/L)	66.02 $\pm$ 21.55 (5.64–307.1)
BMI (kg/m ²)	23.92 $\pm$ 3.13 (13.31–34.03)
ApoE genotype (%)	
$\epsilon 2/\epsilon 2$	$n = 20$ (3.27)
$\epsilon 2/\epsilon 3$	$n = 66$ (10.80)
$\epsilon 2/\epsilon 4$	$n = 17$ (2.78)
$\epsilon 3/\epsilon 3$	$n = 414$ (67.76)
$\epsilon 3/\epsilon 4$	$n = 88$ (14.40)
$\epsilon 4/\epsilon 4$	$n = 6$ (0.98)

tract, chronic alcohol abuse, or thiamine supplementation during the previous month were excluded from this study.

A flowchart of the study protocol and demographic information on the participants are shown in Fig.1 and Table 1. The study design and procedures were approved by the Committee on Medical Ethics of Zhongshan Hospital, Fudan University.

Clinical Assessments

All participants completed the Mini-Mental State Examination (MMSE, Chinese version) as a measure of general cognitive function, with scores ranging from 0 (severe impairment) to 30 (no impairment). The non-demented elderly were identified according to the MMSE score adjusted for educational background: illiterate individuals with MMSE scores >17 , participants with a preliminary school diploma and scores >21 , and

participants with >9 years of education and scores >24 . Individuals who did not meet the above criteria were excluded. Routine blood parameters, liver and kidney functions, and levels of fasting blood glucose (FBG) and triglycerides were measured. Height and weight were used to calculate body mass index (BMI).

Determination of Thiamine, TMP, and TDP Levels

The levels of thiamine, TMP, and TDP were measured using HPLC as previously described in detail^[18]. Briefly, 150 μ L of 7.4% perchloric acid was immediately added to 150 μ L of fresh blood anti-coagulated with heparin. After mixing by vibration for 30 s for full deproteinization, the mixture was centrifuged at 10 000 rpm for 6 min at 4°C. Then, the supernatant was collected and stored at -20°C until determination. Thiamine and its phosphate esters were derivatized into thiochromes using potassium ferricyanide and separated by gradient elution on a C18 reversed-phase analytical column (250 mm $\times$ 4.6 mm). The derivatives were measured by HPLC fluoroscopy (Agilent 1100, Santa Clara, CA) at 367 nm excitation and 435 nm emission. Thiamine, TMP, and TDP levels were quantified using standard samples of each compound (Sigma-Aldrich, St. Louis, MO).

Apolipoprotein E Genotype Analysis

APOE alleles were detected using the ABI real-time Taqman SNP genotyping assay (Life Technologies, Carlsbad, CA) according to the manufacturer's instructions. Human genomic DNA was extracted from blood anti-coagulated with heparin using a genome extraction kit (Tiangen Biotech, Beijing, China). All participants were divided into two subgroups by the *APOE* genotype: according to the presence of *APOE* $\epsilon 2$ allele, an *APOE* $\epsilon 2$ positive group with the $\epsilon 2/\epsilon 2$, $\epsilon 2/\epsilon 3$, or $\epsilon 2/\epsilon 4$ genotype and a negative group with the $\epsilon 3/\epsilon 3$, $\epsilon 3/\epsilon 4$, or $\epsilon 4/\epsilon 4$ genotype; according to the presence of *APOE* $\epsilon 4$ allele, an *APOE* $\epsilon 4$ -positive group with the $\epsilon 2/\epsilon 4$, $\epsilon 3/\epsilon 4$, or $\epsilon 4/\epsilon 4$ genotype and an *APOE* $\epsilon 4$ -negative group with the $\epsilon 2/\epsilon 2$, $\epsilon 2/\epsilon 3$, or $\epsilon 3/\epsilon 3$ genotype.

Statistical Analysis

SPSS software (version 18.0; SPSS Inc., Chicago, IL) was used for statistical analyses. Pearson correlation analysis was used to assess the correlation between thiamine metabolite levels and MMSE scores. Two-tailed Student's

t-test or one-way analysis of variance (ANOVA) was used to assess differences in TDP, TMP, and thiamine levels. All data are shown as mean $\pm$ SD, with statistical significance set at <0.05 .

RESULTS

Participants

Eight hundred and thirty individuals underwent routine physical examination in the Regional Health Service Center of Xujiahui, Shanghai and 783 agreed to participate in this study. Among these, 120 had a history of supplementation with thiamine and its analogues in the last month and were

excluded. Six hundred and sixty-three individuals then received MMSE evaluation and 27 with low scores were excluded. Finally, the blood thiamine, TMP, and TDP levels were measured in 636 non-demented individuals. Based on the 95% confidence intervals (CI) of blood thiamine, TMP, and TDP levels, 611 participants were enrolled in our study. Detailed demographic information on the participants is shown in Table 1.

TDP Level Weakly Correlated with MMSE Score

TDP concentration showed a weakly-positive correlation with MMSE score ($r = 0.1492$, $P < 0.001$, Fig. 2A), while the TMP and thiamine levels did not (TMP: $r = 0.0233$,

Fig. 2. TDP concentration shows a positive correlation with MMSE. A. TDP concentration showed a weak but significantly positive correlation with MMSE score. B. TMP concentration had no significant correlation with MMSE score. C. Thiamine concentration had no correlation with MMSE score.

Fig. 3. A high TDP level is associated with better cognitive performance. A. Participants with high TDP levels (≥ 99.48 nmol/L, $n = 485$) performed better in *Recall* than those with low TDP levels (< 99.48 nmol/L, $n = 126$, 2.37 ± 0.04 vs 2.11 ± 0.09 , $P < 0.01$). B. Participants with high TDP levels performed better in *Attention and Calculation* than those with low TDP levels (4.45 ± 0.05 vs 4.20 ± 0.14 , $P < 0.05$). C. There was no significant difference in *Registration* between participants with high TDP levels and low TDP levels (2.93 ± 0.01 vs 2.91 ± 0.03 , $P > 0.05$).

Table 2. Effects of age, gender, BMI, blood hemoglobin, fasting plasma glucose, and triglyceride levels on blood thiamine metabolite values

	TDP (nmol/L)	TMP (nmol/L)	Thiamine (nmol/L)
<i>APOE</i> genotype			
ε2 (ε2/ε2, ε2/ε3, ε2/ε4, <i>n</i> = 103)	123.1 ± 23.52	3.93 ± 2.26	3.62 ± 2.79
non-ε2 (ε3/ε3, ε3/ε4, ε4/ε4, <i>n</i> = 508)	117.7 ± 23.12	3.66 ± 2.14	3.44 ± 2.80
<i>P</i>	0.0334	ns	ns
ε4 (ε2/ε4, ε3/ε4, ε4/ε4, <i>n</i> = 111)	117.9 ± 22.94	3.41 ± 2.01	3.44 ± 2.44
non-ε4 (ε2/ε2, ε2/ε3, ε3/ε3, <i>n</i> = 500)	118.8 ± 23.34	3.77 ± 2.19	3.47 ± 2.88
<i>P</i>	ns	ns	ns
Age (years)			
≤70 (<i>n</i> = 271)	121.9 ± 22.81	3.96 ± 2.17	3.47 ± 2.56
71–80 (<i>n</i> = 288)	116.8 ± 22.89	3.53 ± 2.14	3.50 ± 3.07
>80 (<i>n</i> = 52)	112.0 ± 25.36	3.32 ± 2.10	3.29 ± 2.41
<i>P</i>	0.0033	0.0275	ns
Gender			
Male (<i>n</i> = 263)	118.9 ± 23.02	3.19 ± 1.86	2.96 ± 2.28
Female (<i>n</i> = 348)	118.4 ± 23.46	4.09 ± 2.28	3.85 ± 3.08
<i>P</i>	ns	<0.001	<0.001
Educational background			
<9 years (<i>n</i> = 169)	114.3 ± 23.93	3.68 ± 2.42	3.57 ± 3.60
≥9 years (<i>n</i> = 442)	120.3 ± 22.79	3.71 ± 2.05	3.43 ± 2.43
<i>P</i>	0.0042	ns	ns
BMI (kg/m ²) [§]			
<20 (<i>n</i> = 57)	110.5 ± 21.64	3.82 ± 2.07	3.91 ± 2.56
20–25 (<i>n</i> = 327)	118.8 ± 23.49	3.88 ± 2.20	3.45 ± 2.93
>25 (<i>n</i> = 204)	121.5 ± 22.86	3.52 ± 2.14	3.42 ± 2.72
<i>P</i>	<0.0064	ns	ns
Hemoglobin (g/L)			
<120 (<i>n</i> = 71)	104.2 ± 22.61	3.45 ± 2.03	3.68 ± 2.51
≥120 (<i>n</i> = 540)	120.6 ± 22.68	3.74 ± 2.17	3.44 ± 2.84
<i>P</i>	<0.001	ns	ns
Fasting blood glucose			
<6.1 mmol/L (<i>n</i> = 439)	116.7 ± 23.48	3.71 ± 2.18	3.34 ± 2.70
≥6.1 mmol/L (<i>n</i> = 172)	123.5 ± 21.99	3.69 ± 2.11	3.78 ± 2.02
<i>P</i>	0.0011	ns	ns
Triglycerides (mmol/L)			
≤1.7 (<i>n</i> = 449)	116.4 ± 22.91	3.71 ± 2.10	3.43 ± 2.73
>1.7 (<i>n</i> = 162)	124.8 ± 23.13	3.67 ± 2.31	3.56 ± 3.00
<i>P</i>	<0.001	ns	ns

[§]BMI: Height and weight data not available for 23 participants.

$P = 0.565$; thiamine: $r = 0.0623$, $P = 0.124$, Fig. 2B, C). We further analyzed the MMSE scores on sub-items in different subgroups divided according to TDP level. Based on the TDP cut-off level of 99.48 nmol/L (taken as the lower value to distinguish AD from controls as calculated by ROC analysis, unpublished data), participants with high TDP levels (≥ 99.48 nmol/L, $n = 485$) performed better in *Recall*, and *Attention and Calculation* than those with low TDP levels (< 99.48 nmol/L, $n = 126$; *Recall*: 2.37 ± 0.04 versus 2.11 ± 0.09 , $P < 0.01$; *Attention and Calculation*: 4.45 ± 0.05 vs 4.20 ± 0.14 , $P < 0.05$). There was no significant difference in *Registration* between the two groups (2.93 ± 0.01 vs 2.91 ± 0.03 , $P > 0.05$, Fig. 3A–C).

Effects of APOE Genotype, Age, Gender, Educational Background, BMI, Hemoglobin, FBG, and Triglycerides on the Blood Levels of Thiamine Metabolites

To assess the possible metabolic and social factors that affect the status of thiamine metabolism in non-demented elderly people, we investigated the effects of APOE genotype, age, gender, educational background, BMI, hemoglobin, FBG, and triglycerides on the levels of blood thiamine metabolites. The frequency of the APOE $\epsilon 2$ allele was 16.86% (103/611: $\epsilon 2/\epsilon 2$, 20; $\epsilon 2/\epsilon 3$, 66; $\epsilon 2/\epsilon 4$, 17). TDP levels in APOE $\epsilon 2$ -positive participants were significantly higher than those in APOE $\epsilon 2$ -negative participants. One hundred and eleven participants were APOE $\epsilon 4$ carriers ($\epsilon 2/\epsilon 4$, 17; $\epsilon 3/\epsilon 4$, 88; $\epsilon 4/\epsilon 4$, 6). There was no significant difference in TDP level between APOE $\epsilon 4$ -positive and $\epsilon 4$ -negative participants. There were no significant differences in TMP and thiamine levels between participants positive or negative for the APOE $\epsilon 2$ or $\epsilon 4$ allele (Table 2).

We divided the participants into three subgroups according to age: ≤ 70 years, $n = 271$; 71–80, $n = 288$; > 80 , $n = 52$. Blood TDP and TMP concentrations showed a significantly decreased trend with aging (Table 2). TDP levels were not significantly different between male and female participants (Table 2). Surprisingly, both TMP and thiamine concentrations were lower in male than in female participants (both $P < 0.001$). Participants with a better educational background tended to have higher TDP levels than those with relatively little education ($P < 0.01$, Table 2).

Blood TDP levels in participants with a higher BMI were higher than that in those with a lower BMI ($P < 0.01$). Since TDP is mostly present in red blood cells, we further

analyzed whether blood hemoglobin level affects the TDP level. We found that TDP levels were significantly higher in participants with hemoglobin levels > 120 g/L than in those with < 120 g/L ($P < 0.001$). In addition, TDP levels were significantly lower in participants with FBG levels < 6.1 mmol/L than in those with > 6.1 mmol/L ($P < 0.05$). However, there were no significant differences in TMP and thiamine levels between the two subgroups. TDP levels in participants with triglyceride levels < 1.7 mmol/L were significantly lower than in those with > 1.7 mmol/L ($P < 0.001$). Also, there were no significant differences in TMP and thiamine levels between participants with triglycerides > 1.7 mmol/L and < 1.7 mmol/L (Table 2).

DISCUSSION

Cerebral glucose hypometabolism is an early change and correlates with the severity of cognitive decline in individuals with mild cognitive impairment (MCI) and patients with dementia^[8, 19–21]. As a key coenzyme in glucose metabolism, TDP has been reported to decrease in AD, the most common type of dementia^[22–24]. The activities of TDP-dependent enzymes are also significantly lessened in AD. Studies have revealed that the activity of brain α -ketoglutarate dehydrogenase complex declines $> 75\%$, TK activity declines $> 45\%$, and pyruvate dehydrogenase complex activity declines up to 41% in AD patients^[10, 25]. Further, mild to moderate thiamine deficiency is prevalent in elderly people^[26–28]. Hence, it is imperative to clarify the correlation between the levels of thiamine metabolites and cognitive function, which may provide a target to prevent cognitive decline in non-demented elderly.

In this study, we found a significantly positive correlation between TDP levels and MMSE scores in the non-demented elderly (Fig. 2). This result is consistent with that in the studies of La Rue, Ortega, and Requejo^[13, 15, 29]. More importantly, further analysis of the sub-items of MMSE showed that participants with high TDP levels performed better in *Recall*, and *Attention and Calculation*, but not in *Registration* (Fig. 3). Previous studies have demonstrated that the test of delayed recall can discriminate individuals with MCI and very mild AD from normal elderly with high accuracy^[30–32]. Impaired delayed memory is also an excellent predictor of conversion from MCI to AD^[33, 34]. Hence, sustaining normal or even higher TDP levels in the

elderly may help to maintain delayed recall and prevent long-term memory decline.

The *APOE* gene is one of the most common genetic factors associated with dementia^[35], especially AD, and the *APOE* ϵ 4 allele is a risk factor for AD^[36, 37]. Meanwhile, the *APOE* ϵ 2 allele has a protective effect against cognitive decline compared to the *APOE* ϵ 3 and ϵ 4 alleles^[38–41]. In the current study, the TDP levels in *APOE* ϵ 2-positive participants were significantly higher than those in ϵ 2-negative participants, but there was no significant difference in TDP levels between *APOE* ϵ 4-positive and ϵ 4-negative participants (Table 2). However, cognitive status did not differ between *APOE* ϵ 2-positive and ϵ 2-negative participants (Fig. S1), which suggested that the effect of the *APOE* ϵ 2 allele on TDP levels is independent of cognitive function. Further exploration is needed to clarify the relationship between the *APOE* genotype and thiamine metabolism.

Aging appeared to have a negative effect on the levels of thiamine metabolites. We found that the levels of blood TDP and TMP, but not thiamine, decreased with aging in the non-demented elderly (Table 2), consistent with previous studies^[26–28]. A more balanced or improved diet pattern with thiamine-enriched food should be advocated for the elderly.

In addition, no significant difference in blood TDP levels was found between male and female participants (Table 2). But surprisingly, blood TMP and thiamine levels were significantly higher in females than in males. The mechanism by which gender impacts the levels of thiamine metabolite needs to be clarified.

Recently, Qizilbash and colleagues found that underweight people (BMI <20 kg/m²) have a 34% higher risk of dementia than those with a healthy weight^[42]. In our study, BMI had a substantially positive effect on blood TDP concentration, which was positively correlated with cognitive function. In addition, we found that hemoglobin levels were correlated with TDP concentrations. TDP levels were higher in the subgroup with hemoglobin levels >120 g/L than in the subgroup with hemoglobin levels <120 g/L (Table 2). These results reflect the fact that blood TDP mainly exists in red blood cells.

In summary, we found a positive correlation between blood TDP levels and cognitive function in non-demented elderly Chinese, especially in *Recall* and *Attention and Calculation*. We also investigated the effects of the *APOE*

ϵ 2 allele, BMI, and other factors on the levels of thiamine metabolites. Considering its critical role in cerebral glucose metabolism, we conclude that the levels of TDP, the active form of thiamine that is easily affected by multiple factors, correlate with cognitive function and provide a potential target against cognitive decline in the elderly. However, the status of thiamine metabolism *in vivo* is complicated and easily affected by many biological and social factors. When we used a multiple linear regression model to analyze the impact factors for TDP levels, the results had some minor differences from those deduced from simple regression (Table S1), such as gender. This may be partly due to the differences in age and educational level between male and female participants. In future studies, analysis by multiple linear regression should be conducted in a larger population to explore in more detail the relationships between TDP level and its impact factors.

ELECTRONIC SUPPLEMENTARY MATERIAL

Supplementary material is available in the online version of this article at <http://dx.doi.org/10.1007/s12264-015-1563-3>.

ACKNOWLEDGMENTS

This work was supported by the National Basic Research Development Program (973 Program) of China (2011CBA00400), the National Natural Science Foundation of China (91332201), the Natural Science Foundation of Shanghai Municipality, China (13JC1401501), and the Fund for Medical Emerging Cutting-edge Technology of Shanghai Municipality, China (SHDC12012114).

REFERENCES

- [1] de Castro IP, Martins LM, Tufi R. Mitochondrial quality control and neurological disease: an emerging connection. *Expert Rev Mol Med* 2010, 12: e12.
- [2] Bouzier-Sore AK, Voisin P, Bouchaud V, Bezancon E, Franconi JM, Pellerin L. Competition between glucose and lactate as oxidative energy substrates in both neurons and astrocytes: a comparative NMR study. *Eur J Neurosci* 2006, 24: 1687–1694.
- [3] Davidson MB. The effect of aging on carbohydrate metabolism: a review of the English literature and a practical approach to the diagnosis of diabetes mellitus in the elderly. *Metabolism* 1979, 28: 688–705.
- [4] J SR-F, Sa-Roriz TM, Rosset I, Camozzato AL, Santos AC, Chaves ML, *et al.* (Pre)diabetes, brain aging, and cognition.

- Biochim Biophys Acta 2009, 1792: 432–443.
- [5] Mosconi L, Pupi A, De Cristofaro MT, Fayyaz M, Sorbi S, Herholz K. Functional interactions of the entorhinal cortex: an 18F-FDG PET study on normal aging and Alzheimer's disease. *J Nucl Med* 2004, 45: 382–392.
- [6] Mosconi L, Sorbi S, de Leon MJ, Li Y, Nacmias B, Myoung PS, *et al.* Hypometabolism exceeds atrophy in presymptomatic early-onset familial Alzheimer's disease. *J Nucl Med* 2006, 47: 1778–1786.
- [7] Brys M, Pirraglia E, Rich K, Rolstad S, Mosconi L, Switalski R, *et al.* Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment. *Neurobiol Aging* 2009, 30: 682–690.
- [8] Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC, *et al.* Clinical and biomarker changes in dominantly inherited Alzheimer's disease. *N Engl J Med* 2012, 367: 795–804.
- [9] Wilkinson TJ, Hanger HC, George PM, Sainsbury R. Is thiamine deficiency in elderly people related to age or co-morbidity? *Age Ageing* 2000, 29: 111–116.
- [10] Gibson GE, Sheu KF, Blass JP, Baker A, Carlson KC, Harding B, *et al.* Reduced activities of thiamine-dependent enzymes in the brains and peripheral tissues of patients with Alzheimer's disease. *Arch Neurol* 1988, 45: 836–840.
- [11] Mastrogicola F, Bettendorff L, Grisar T, Kish SJ. Brain thiamine, its phosphate esters, and its metabolizing enzymes in Alzheimer's disease. *Ann Neurol* 1996, 39: 585–591.
- [12] Gold M, Hauser RA, Chen MF. Plasma thiamine deficiency associated with Alzheimer's disease but not Parkinson's disease. *Metab Brain Dis* 1998, 13: 43–53.
- [13] La Rue A, Koehler KM, Wayne SJ, Chiulli SJ, Haaland KY, Garry PJ. Nutritional status and cognitive functioning in a normally aging sample: a 6-y reassessment. *Am J Clin Nutr* 1997, 65: 20–29.
- [14] McNeill G, Jia X, Whalley LJ, Fox HC, Corley J, Gow AJ, *et al.* Antioxidant and B vitamin intake in relation to cognitive function in later life in the Lothian Birth Cohort 1936. *Eur J Clin Nutr* 2011, 65: 619–626.
- [15] Ortega RM, Requejo AM, Andres P, Lopez-Sobaler AM, Quintas ME, Redondo MR, *et al.* Dietary intake and cognitive function in a group of elderly people. *Am J Clin Nutr* 1997, 66: 803–809.
- [16] Lu J, Frank EL. Rapid HPLC measurement of thiamine and its phosphate esters in whole blood. *Clin Chem* 2008, 54: 901–906.
- [17] Korner RW, Vierzig A, Roth B, Muller C. Determination of thiamin diphosphate in whole blood samples by high-performance liquid chromatography—a method suitable for pediatric diagnostics. *J Chromatogr B Analyt Technol Biomed Life Sci* 2009, 877: 1882–1886.
- [18] Pan X, Gong N, Zhao J, Yu Z, Gu F, Chen J, *et al.* Powerful beneficial effects of benfotiamine on cognitive impairment and beta-amyloid deposition in amyloid precursor protein/presenilin-1 transgenic mice. *Brain* 2010, 133: 1342–1351.
- [19] Mosconi L. Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. *FDG-PET studies in MCI and AD. Eur J Nucl Med Mol Imaging* 2005, 32: 486–510.
- [20] Mosconi L, Pupi A, De Leon MJ. Brain glucose hypometabolism and oxidative stress in preclinical Alzheimer's disease. *Ann N Y Acad Sci* 2008, 1147: 180–195.
- [21] Lo RY, Hubbard AE, Shaw LM, Trojanowski JQ, Petersen RC, Aisen PS, *et al.* Longitudinal change of biomarkers in cognitive decline. *Arch Neurol* 2011, 68: 1257–1266.
- [22] Gibson GE, Blass JP. Thiamine-dependent processes and treatment strategies in neurodegeneration. *Antioxid Redox Signal* 2007, 9: 1605–1619.
- [23] Lu'o'ng K, Nguyen LT. Role of thiamine in Alzheimer's disease. *Am J Alzheimers Dis Other Dement* 2011, 26: 588–598.
- [24] Chen Z, Zhong C. Decoding Alzheimer's disease from perturbed cerebral glucose metabolism: implications for diagnostic and therapeutic strategies. *Prog Neurobiol* 2013, 108: 21–43.
- [25] Sheu KF, Kim YT, Blass JP, Weksler ME. An immunochemical study of the pyruvate dehydrogenase deficit in Alzheimer's disease brain. *Ann Neurol* 1985, 17: 444–449.
- [26] O'Rourke NP, Bunker VW, Thomas AJ, Finglas PM, Bailey AL, Clayton BE. Thiamine status of healthy and institutionalized elderly subjects: analysis of dietary intake and biochemical indices. *Age Ageing* 1990, 19: 325–329.
- [27] Pepersack T, Garbusinski J, Robberecht J, Beyer I, Willems D, Fuss M. Clinical relevance of thiamine status amongst hospitalized elderly patients. *Gerontology* 1999, 45: 96–101.
- [28] O'Keeffe ST, Tormey WP, Glasgow R, Lavan JN. Thiamine deficiency in hospitalized elderly patients. *Gerontology* 1994, 40: 18–24.
- [29] Requejo AM, Ortega RM, Robles F, Navia B, Faci M, Aparicio A. Influence of nutrition on cognitive function in a group of elderly, independently living people. *Eur J Clin Nutr* 2003, 57 Suppl 1: S54–57.
- [30] Baek MJ, Kim HJ, Ryu HJ, Lee SH, Han SH, Na HR, *et al.* The usefulness of the story recall test in patients with mild cognitive impairment and Alzheimer's disease. *Neuropsychol Dev Cogn B Aging Neuropsychol Cogn* 2011, 18: 214–229.
- [31] Sano M, Raman R, Emond J, Thomas RG, Petersen R, Schneider LS, *et al.* Adding delayed recall to the Alzheimer Disease Assessment Scale is useful in studies of mild cognitive impairment but not Alzheimer disease. *Alzheimer Dis Assoc Disord* 2011, 25: 122–127.
- [32] Gainotti G, Quaranta D, Vita MG, Marra C. Neuropsychol

- chological predictors of conversion from mild cognitive impairment to Alzheimer's disease. *J Alzheimers Dis* 2014, 38: 481–495.
- [33] Chen P, Ratcliff G, Belle SH, Cauley JA, DeKosky ST, Ganguli M. Cognitive tests that best discriminate between presymptomatic AD and those who remain nondemented. *Neurology* 2000, 55: 1847–1853.
- [34] Grober E, Lipton RB, Hall C, Crystal H. Memory impairment on free and cued selective reminding predicts dementia. *Neurology* 2000, 54: 827–832.
- [35] Dorey E, Chang N, Liu QY, Yang Z, Zhang W. Apolipoprotein E, amyloid-beta, and neuroinflammation in Alzheimer's disease. *Neurosci Bull* 2014, 30: 317–330.
- [36] Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, *et al.* Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. *Science* 1993, 261: 921–923.
- [37] Rebeck GW, Reiter JS, Strickland DK, Hyman BT. Apolipoprotein E in sporadic Alzheimer's disease: allelic variation and receptor interactions. *Neuron* 1993, 11: 575–580.
- [38] Bu G. Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy. *Nat Rev Neurosci* 2009, 10: 333–344.
- [39] Blacker D, Lee H, Muzikansky A, Martin EC, Tanzi R, McArdle JJ, *et al.* Neuropsychological measures in normal individuals that predict subsequent cognitive decline. *Arch Neurol* 2007, 64: 862–871.
- [40] Martins CA, Oulhaj A, de Jager CA, Williams JH. APOE alleles predict the rate of cognitive decline in Alzheimer disease: a nonlinear model. *Neurology* 2005, 65: 1888–1893.
- [41] Blair CK, Folsom AR, Knopman DS, Bray MS, Mosley TH, Boerwinkle E, *et al.* APOE genotype and cognitive decline in a middle-aged cohort. *Neurology* 2005, 64: 268–276.
- [42] Qizilbash N, Gregson J, Johnson ME, Pearce N, Douglas I, Wing K, *et al.* BMI and risk of dementia in two million people over two decades: a retrospective cohort study. *Lancet Diabetes Endocrinol* 2015.